2. Search Result
Search Result
Results for "

liver disorder

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

4

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156527
    PHD-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cancer
    PHD-IN-2 (Compound 91) is a PHD antagonist (IC50: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC50: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .
    PHD-IN-2
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-145157
    Ferric nitrilotriacetate

    		Others Others
    Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis .
    Ferric nitrilotriacetate
  • HY-148264
    Imdatifan

    HIF-2α-IN-7

    		 HIF/HIF Prolyl-Hydroxylase Infection Metabolic Disease Inflammation/Immunology Cancer
    Imdatifan (HIF-2α-IN-7) is a hypoxia inducible factor 2α (HIF-2α) inhibitor. Imdatifan can inhibit HIF-2α with an EC50 value of 6 nM. Imdatifan can be used for the research of various types of diseases including cancer, liver disease, inflammatory disease, pulmonary diseases and iron load disorders .
    Imdatifan
  • HY-151487
    CypD-IN-3

    		Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-3 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-3 has CypD affinity with an IC50 value of 0.01 μM. CypD-IN-3 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-3
  • HY-151488
    CypD-IN-4

    		Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-4 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-4 has CypD affinity with an IC50 value of 0.057 μM. CypD-IN-4 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-4
  • HY-N2868
    Andropanoside

    		Others Metabolic Disease
    Andropanoside is a natural product and possesses a protective activity against various liver disorders .
    Andropanoside
  • HY-151489
    CypE-IN-1

    		Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-1 is a potent and subtype-selective cyclophilin E (CypE) inhibitor. CypD-IN-1 has CypE affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. CypD-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypE-IN-1
  • HY-B1337S5
    Choline-13C2 chloride

    		nAChR Endogenous Metabolite Cancer
    Choline- 13C2 (chloride) is the 13C labeled Choline chloride[1]. Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders[2][3].
    Choline-13C2 chloride
  • HY-B1337
    Choline chloride
    2 Publications Verification

    		 nAChR Endogenous Metabolite Cancer
    Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .
    Choline chloride
  • HY-148795
    Ritivixibat

    		Apical Sodium-Dependent Bile Acid Transporter Cardiovascular Disease Metabolic Disease
    Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases .
    Ritivixibat
  • HY-B1337B
    Glycerophosphoinositol choline

    		nAChR Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Glycerophosphoinositol choline is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .
    Glycerophosphoinositol choline
  • HY-101036
    Choline bitartrate
    2 Publications Verification
    Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .
    Choline bitartrate
  • HY-47888
    PLN-1474

    		Integrin Inflammation/Immunology
    PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.
    PLN-1474
  • HY-157601
    HSD17B13-IN-4

    		17β-HSD Metabolic Disease
    HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-4
  • HY-157613
    HSD17B13-IN-5

    		17β-HSD Metabolic Disease
    HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-5
  • HY-W016145
    L-Glutamic acid monosodium (hydrate)

    		Apoptosis Metabolic Disease Cancer
    L-Glutamic acid monosodium hydrate is a nutritional additive and flavoring agent. L-Glutamic acid monosodium hydrate can reduce obesity and induce metabolic disorders associated with oxidative stress. L-Glutamic acid monosodium hydrate induces oxidative stress,DNA damage and apoptosis in the liver and brain tissues of mice .
    L-Glutamic acid monosodium (hydrate)
  • HY-161213
    HSD17B13-IN-11

    		17β-HSD Metabolic Disease
    HSD17B13-IN-11 (Compound 2) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-11 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-11
  • HY-161214
    HSD17B13-IN-12

    		17β-HSD Metabolic Disease
    HSD17B13-IN-12 (Compound 3) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. HSD17B13-IN-12 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-12
  • HY-161215
    HSD17B13-IN-14

    		17β-HSD Metabolic Disease
    HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-14
  • HY-161216
    HSD17B13-IN-15

    		17β-HSD Metabolic Disease
    HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
    HSD17B13-IN-15
  • HY-B1134
    Imazalil
    1 Publications Verification

    Enilconazole

    		 Fungal Infection
    Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .
    Imazalil
  • HY-14908
    Vidofludimus
    2 Publications Verification

    4sc-101; SC12267

    		 Dihydroorotate Dehydrogenase Interleukin Related FXR Infection Inflammation/Immunology
    Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .
    Vidofludimus
  • HY-B1134A
    Imazalil sulfate

    Enilconazolel sulfate

    		 Fungal Infection
    Imazalil (Enilconazole) sulfate is a fungicide. Imazalil sulfate has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil sulfate is commonly used to protect various agricultural crops against fungal attack. Imazalil sulfate induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .
    Imazalil sulfate
  • HY-149481
    D4R agonist-1

    		Dopamine Receptor Neurological Disease
    D4R agonist-1 (Compound 16f) is a D4R partial agonist (Ki: 2.2 nM). D4R agonist-1 is metabolically stable in rat and human liver microsomes. D4R agonist-1 can be used for research of neuropsychiatric disorders .
    D4R agonist-1
  • HY-134781
    CKK-E12
    1 Publications Verification

    		 Liposome Others
    CKK-E12 is a ionizable lipid in combination with other lipids make up the lipid nanoparticles which are used to deliver RNA-based research. CKK-E12 is highly selective toward liver parenchymal cell in vivo,
    CKK-E12
  • HY-157667
    HSD17B13-IN-44

    		17β-HSD Metabolic Disease
    HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-44
  • HY-157671
    HSD17B13-IN-45

    		17β-HSD Metabolic Disease
    HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-45
  • HY-157674
    HSD17B13-IN-46

    		17β-HSD Metabolic Disease
    HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-46
  • HY-157676
    HSD17B13-IN-47

    		17β-HSD Metabolic Disease
    HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-47
  • HY-157708
    HSD17B13-IN-67

    		17β-HSD Metabolic Disease
    HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-67
  • HY-157710
    HSD17B13-IN-68

    		17β-HSD Metabolic Disease
    HSD17B13-IN-68 (Compound 16) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-68 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-68
  • HY-157717
    HSD17B13-IN-70

    		17β-HSD Metabolic Disease
    HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-70
  • HY-157720
    HSD17B13-IN-72

    		17β-HSD Metabolic Disease
    HSD17B13-IN-72 (Compound 62) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-72 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-72
  • HY-157722
    HSD17B13-IN-73

    		17β-HSD Metabolic Disease
    HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-73
  • HY-157723
    HSD17B13-IN-74

    		17β-HSD Metabolic Disease
    HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-74
  • HY-157724
    HSD17B13-IN-76

    		17β-HSD Metabolic Disease
    HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-76
  • HY-157726
    HSD17B13-IN-77

    		17β-HSD Metabolic Disease
    HSD17B13-IN-77 (Compound 808) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-77 can be used for research on liver diseases or metabolic disorders .
    HSD17B13-IN-77
  • HY-14908A
    Vidofludimus hemicalcium

    4sc-101 hemicalcium; SC12267 hemicalcium

    		 Dihydroorotate Dehydrogenase Interleukin Related FXR Infection Inflammation/Immunology
    Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .
    Vidofludimus hemicalcium
  • HY-W105505
    SAMe-1,4-Butanedisulfonate

    		Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    SAMe-1,4-Butanedisulfonate, a natural compound, is a methyl donor in the central nervous system. SAMe-1,4-Butanedisulfonate has antidepressant activity. SAMe-1,4-Butanedisulfonate can be used for research of CNS disorders .
    SAMe-1,4-Butanedisulfonate
  • HY-14280S
    Entacapone-d10

    		COMT Neurological Disease
    Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].
    Entacapone-d10
  • HY-14280S2
    (E)-Entacapone-d10

    		COMT Neurological Disease
    (E)-Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].
    (E)-Entacapone-d10
  • HY-117006
    E1231

    1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one

    		 Sirtuin Cardiovascular Disease
    E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE -/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .
    E1231
  • HY-14280
    Entacapone
    4 Publications Verification

    		 COMT Neurological Disease Cancer
    Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone
  • HY-14280A
    Entacapone sodium salt

    		COMT Neurological Disease
    Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease . Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone sodium salt
  • HY-14280R
    Entacapone (Standard)

    		COMT Neurological Disease Cancer
    Entacapone (Standard) is the analytical standard of Entacapone. This product is intended for research and analytical applications. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: